The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

April 2, 2014 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease
Explore This Issue
April 2014
Also By This Author
  • ACR Winter Rheumatology Symposium: The Search for Answers in Sjögren’s Syndrome
Spondylarthritis

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

SNOWMASS,CO—Spondyloarthritis (SpA) is a group of several related but phenotypically distinct disorders: psoriatic arthritis (PsA), arthritis related to inflammatory bowel disease, reactive arthritis, a subgroup of juvenile idiopathic arthritis and ankylosing spondylitis (AS). Early treatment of SpA is key, according to Christopher T. Ritchlin, MD, MPH, professor of medicine and director, Translational Immunology Research Center, University of Rochester (N.Y.) Medical Center.

During his presentation, Shifting Sands: Bone Formation and Degradation in Spondyloarthritis at the ACR’s Winter Rheumatology Symposium, Dr. Ritchlin noted that treatment during the early stages of osteitis may stop molecular switching to the bone-forming phenotype that is characteristic of SpA. Treatments that he discussed for their promise in preventing disease progression include tumor necrosis factor inhibitors (TNFi), nonsteroidal anti-inflammatory drugs (NSAIDs) and ustekinumab.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Bone Remodeling

Normal bone remodeling includes a four-part cycle. During resorption, osteoclasts remove bone mineral and matrix to create an erosion cavity. During reversal, mononuclear cells prepare bone surface for new osteoblasts to begin building bone. During formation, osteoblasts synthesize a matrix to replace resorbed bone with new bone. And finally, the resting phase is a prolonged period that occurs until a new remodeling cycle begins.

“Three different groups of molecules direct mesenchymal cells to differentiate into osteoblasts,” Dr. Ritchlin explained. “The first is the BMP [bone morphogenetic proteins] pathway, which triggers the SMAD signaling pathway.” BMPs are cytokines that are involved in the formation of bone and cartilage.

The second group of molecules is the Wnt signaling pathway. “Wnts are secreted glycoproteins that bind to the LRP56, which then couples with the G protein-like Fr Receptor and phosphorylates b catenin that then crosses into the nucleus to initiate transcription of genes involved in osteoblast differentiation,” Dr. Ritchlin said. “Inhibitors of this pathway include the sol Frz R protein, DKK-1 and sclerostin. Interestingly, DKK-1 and sclerostin levels are low in AS, and DKK-2 receptor signaling is defective in AS, which may help explain the anabolic nature of the disease.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The third pathway is PGE2, which is an important pathway for promoting osteoblast differentiation. “In fact, NSAIDs can inhibit fracture healing and limit heterotopic bone healing, although their therapeutic role in AS is a matter of debate,” Dr. Ritchlin said. “It is important to point out the inter-relationships between these pathways: BMP-2 can induce Wnt-2 expression, and PGE2 can act synergistically with Wnt ligands to increase bone formation.”

Spondylarthritis

The SpA Bone Phenotype

Structural changes in AS are primarily anabolic, Dr. Ritchlin said. “Bony spur formation begins from the cortical bone surface and arises from bony apposition, which has a vertical orientation,” he explained. “Bony spur formation and ankylosis are central features of AS, and evidence suggests that both bony inflammation or osteitis and biomechanical stress are responsible for this phenotype.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: Ankylosing Spondylitis, antiinflammatory, axial spondyloarthritis (SpA), drug, Juvenile idiopathic arthritis, patient care, radiograph, Reactive arthritis, ResearchIssue: April 2014

You Might Also Like:
  • Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease
  • Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.